US2019055196A1PendingUtilityA1

Nuclear receptor modulators

Assignee: ABBVIE INCPriority: Jun 9, 2015Filed: Aug 22, 2018Published: Feb 21, 2019
Est. expiryJun 9, 2035(~8.9 yrs left)· nominal 20-yr term from priority
A61P 37/00A61P 43/00A61P 37/08A61P 37/02A61P 35/00A61P 29/00A61P 27/02C07D 401/10C07D 405/14C07D 403/10A61P 13/12A61K 31/416C07D 491/10A61P 25/00C07D 487/04C07D 235/16A61P 19/08A61K 31/4523A61P 17/00A61K 31/5377C07D 471/04A61P 1/04A61P 19/02A61P 17/06A61P 1/00A61P 19/00C07D 401/14C07D 209/18C07D 235/06A61K 31/454C07D 405/10C07D 209/08C07D 405/12C07D 491/107A61K 31/404C07D 231/56C07D 209/14C07D 401/06
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

Claims

exact text as granted — not AI-modified
1 .- 31 . (canceled) 
     
     
         32 . A compound having the structure: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         33 . A pharmaceutical composition comprising a compound of  claim 32 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

Join the waitlist — get patent alerts

Track US2019055196A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.